<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394365</url>
  </required_header>
  <id_info>
    <org_study_id>ATA129-EBV-302</org_study_id>
    <nct_id>NCT03394365</nct_id>
  </id_info>
  <brief_title>Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy</brief_title>
  <acronym>ALLELE</acronym>
  <official_title>Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical benefit and characterize the safety&#xD;
      profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant&#xD;
      lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT)&#xD;
      after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic&#xD;
      cell transplant (HCT) after failure of rituximab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, phase 3 study to assess the efficacy and safety of&#xD;
      tabelecleucel for the treatment of EBV+ PTLD in the setting of SOT after failure of rituximab&#xD;
      and rituximab plus chemotherapy (SOT cohort) or HCT after failure of rituximab (HCT cohort).&#xD;
&#xD;
      Enrollment will be preceded by confirmation of availability of partially human leukocyte&#xD;
      antigen (HLA) matched and restricted tabelecleucel for the participant.&#xD;
&#xD;
      Study procedures and product administration will be the same for each cohort. Tabelecleucel&#xD;
      will be administered in cycles lasting 5 weeks (35 days). During each cycle, participants&#xD;
      will receive intravenous tabelecleucel at a dose of 2×10^6 cells/kg on Days 1, 8, and 15,&#xD;
      followed by observation through Day 35. Treatment will continue until maximal response,&#xD;
      unacceptable toxicity, initiation of non protocol therapy, or failure of tabelecleucel with&#xD;
      up to 2 different HLA restrictions (SOT cohort) or up to 4 different HLA restrictions (HCT&#xD;
      cohort). The study includes a total of 5 years of follow-up for disease and survival status.&#xD;
&#xD;
      This protocol has been amended to include the HCT cohort from clinical study ATA129-EBV-301&#xD;
      (NCT03392142).&#xD;
&#xD;
      NOTE, 29 April 2020: Enrollment is temporarily paused at study site/locations with status&#xD;
      &quot;active, not recruiting&quot; due to COVID-19 restrictions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) in the SOT or HCT cohort</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) in SOT and HCT cohorts separately</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR and DOR in SOT and HCT cohorts combined</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of complete response (CR) and partial response (PR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of allograft loss or rejection episodes (SOT cohort)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)</condition>
  <condition>Solid Organ Transplant Complications</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <condition>Allogeneic Hematopoietic Cell Transplant</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>SOT cohort -Subgroup A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed rituximab will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOT cohort -Subgroup B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed both rituximab and chemotherapy will receive IV tabelecleucel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCT cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have failed rituximab will receive IV tabelecleucel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tabelecleucel</intervention_name>
    <description>Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.</description>
    <arm_group_label>HCT cohort</arm_group_label>
    <arm_group_label>SOT cohort -Subgroup A</arm_group_label>
    <arm_group_label>SOT cohort -Subgroup B</arm_group_label>
    <other_name>tab-cel®</other_name>
    <other_name>ATA129</other_name>
    <other_name>EBV-CTL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combination of&#xD;
             these (SOT cohort); or prior allogeneic HCT (HCT cohort)&#xD;
&#xD;
          2. A diagnosis of locally-assessed, biopsy-proven EBV+ PTLD&#xD;
&#xD;
          3. Availability of appropriate partially HLA-matched and restricted tabelecleucel has&#xD;
             been confirmed by the sponsor&#xD;
&#xD;
          4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ≥ 3) systemic disease using&#xD;
             Lugano Classification response criteria by positron emission tomography&#xD;
             (PET)-diagnostic computed tomography (CT), except when contraindicated or mandated by&#xD;
             local practice, then magnetic resonance imaging (MRI) may be used.For subjects with&#xD;
             treated central nervous system (CNS) disease, a head CT and/or brain/spinal MRI as&#xD;
             clinically appropriate will be required to follow CNS disease response per Lugano&#xD;
             Classification response criteria.&#xD;
&#xD;
          5. Treatment failure of rituximab or interchangeable commercially available biosimilar&#xD;
             monotherapy (SOT subgroup A or HCT cohort) or rituximab plus any concurrent or&#xD;
             sequentially administered chemotherapy regimen (SOT subgroup B) for treatment of PTLD.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status ≤ 3 for subjects aged ≥ 16&#xD;
             years; Lansky score ≥ 20 for subjects &lt; 16 years&#xD;
&#xD;
          7. For HCT cohort only: If allogeneic HCT was performed as treatment for an acute&#xD;
             lymphoid or myeloid malignancy, the underlying primary disease for which the subject&#xD;
             underwent transplant must be in morphologic remission&#xD;
&#xD;
          8. Adequate organ function&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1000/μL, (SOT cohort) or ≥ 500/μL (HCT cohort), with&#xD;
                  or without cytokine support&#xD;
&#xD;
               2. Platelet count ≥ 50,000/μL, with or without transfusion or cytokine support. For&#xD;
                  HCT cohort, platelet count &lt; 50,000/μL but ≥ 20,000/μL, with or without&#xD;
                  transfusion support, is permissible if the subject has not had grade ≥ 2 bleeding&#xD;
                  in the prior 4 weeks (where grading of the bleeding is determined per the&#xD;
                  National Cancer Institute's Common Terminology Criteria for Adverse Events&#xD;
                  [CTCAE], version 5.0)&#xD;
&#xD;
               3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total&#xD;
                  bilirubin each &lt; 5 × the upper limit of normal; however, ALT, AST, and total&#xD;
                  bilirubin each ≤ 10 × upper limit of normal is acceptable if the elevation is&#xD;
                  considered by the investigator to be due to EBV and/or PTLD involvement of the&#xD;
                  liver as long as there is no known evidence of significant liver dysfunction&#xD;
&#xD;
          9. Subject or subject's representative is willing and able to provide written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Burkitt lymphoma, classical Hodgkin lymphoma, or any T cell lymphoma&#xD;
&#xD;
          2. Daily steroids of &gt; 0.5 mg/kg prednisone or glucocorticoid equivalent, ongoing&#xD;
             methotrexate, or extracorporeal photopheresis&#xD;
&#xD;
          3. Untreated CNS PTLD or CNS PTLD for which the subject is actively receiving&#xD;
             CNS-directed chemotherapy (systemic or intrathecal) or radiotherapy at enrollment.&#xD;
             NOTE:Subjects with previously treated CNS PTLD may enroll if CNS-directed therapy is&#xD;
             complete.&#xD;
&#xD;
          4. Suspected or confirmed grade ≥ 2 graft-versus-host disease (GvHD) per the Center for&#xD;
             International Blood and Marrow Transplant Research consensus grading system at&#xD;
             enrollment&#xD;
&#xD;
          5. Ongoing or recent use of a checkpoint inhibitor agent (eg, ipilimumab, pembrolizumab,&#xD;
             nivolumab) within 3 drug half-lives from the most recent dose to enrollment&#xD;
&#xD;
          6. For HCT cohort: active adenovirus viremia&#xD;
&#xD;
          7. Need for vasopressor or ventilatory support&#xD;
&#xD;
          8. Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          9. Treatment with Epstein-Barr virus cytotoxic T lymphocytes or chimeric antigen receptor&#xD;
             T cells directed against B cells within 8 weeks of enrollment (SOT or HCT cohorts), or&#xD;
             unselected donor lymphocyte infusion within 8 weeks of enrollment (HCT cohort only)&#xD;
&#xD;
         10. Female who is breastfeeding or pregnant or female of childbearing potential or male&#xD;
             with a female partner of childbearing potential unwilling to use a highly effective&#xD;
             method of contraception&#xD;
&#xD;
         11. Inability to comply with study-related procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aditi Mehta, DO</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aditi Mehta, DO</last_name>
    <phone>650-278-8930</phone>
    <phone_ext>1</phone_ext>
    <email>clinicalstudies@atarabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope (Adults and Pediatrics)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandeep Salhotra, MD</last_name>
      <phone>626-256-4673</phone>
      <email>asalhotra@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center (Adults only)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Mulroney, MD</last_name>
      <phone>858-822-8273</phone>
      <email>camulroney@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center (Adults only)</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huynh Cao, MD</last_name>
      <phone>909-558-1000</phone>
      <email>hcao@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neena Kapoor, MD</last_name>
      <phone>323-361-2434</phone>
      <email>nkapoor@chla.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert Eradat, MD</last_name>
      <phone>310-633-8400</phone>
      <email>heradat@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center (Adults only)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Yale University (Adults and Pediatrics)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Valentino, MD</last_name>
      <phone>203-785-4649</phone>
      <email>pamela.valentino@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udeme Ekong, MD</last_name>
      <phone>202-444-3514</phone>
      <email>udeme.d.ekong@gunet.georgetown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida (Adults and Pediatrics)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial Hospital (Adults only)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Beitinjaneh, MD, MPH, MSc</last_name>
      <phone>305-243-9848</phone>
      <email>abeitinjaneh@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston (Pediatrics)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhag Parikh, MD</last_name>
      <phone>404-727-8930</phone>
      <email>suhag.parikh@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University (Adults only)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Koff, MD</last_name>
      <phone>910-540-5145</phone>
      <email>jkoff@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonali Chaudhury, MD</last_name>
      <phone>312-227-4090</phone>
      <email>schaudhury@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satayaijt Kosuri, MD</last_name>
      <phone>773-702-7540</phone>
      <email>skosuri@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Stiff, MD</last_name>
      <phone>708-327-3148</phone>
      <email>pstiff@lumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine (Adults only)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Dahiya, MD</last_name>
      <phone>330-518-9022</phone>
      <email>sdahiya@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute, Brigham and Women's Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Nikiforow, MD</last_name>
      <phone>617-632-6640</phone>
      <email>sarah_nikiforow@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Adults only)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Ghobadi, MD</last_name>
      <phone>314-747-8439</phone>
      <email>arminghobadi@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (Adults only)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (Pediatrics only)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine (Adults only)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Besien, MD</last_name>
      <phone>212-746-2048</phone>
      <email>kov9001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Adults and Pediatrics)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ran Reshef, MD</last_name>
      <phone>212-342-0530</phone>
      <email>rr3036@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Prockop, MD</last_name>
      <phone>212-639-6715</phone>
      <email>prockops@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Children's Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kent, MD</last_name>
      <phone>704-381-9900</phone>
      <email>Michael.kent@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute (Adults only)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew McKinney, MD</last_name>
      <phone>919-684-8111</phone>
      <email>matthew.mckinney@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Adults and Pediatrics)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Rabi, MD</last_name>
      <phone>216-444-0663</phone>
      <email>hannar2@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital (Pediatrics only)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - Arthur G. James Cancer Center Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Baiocchi, MD, PhD</last_name>
      <phone>614-293-3196</phone>
      <email>robert.baiocchi@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nemecek Eneida, MD</last_name>
      <phone>503-494-5058</phone>
      <email>nemeceke@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia (Pediatrics only)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Bunin, MD</last_name>
      <phone>215-590-2255</phone>
      <email>buninn@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (Adults only)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (Adults only)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafic Farah, MD</last_name>
      <phone>412-864-6600</phone>
      <email>farahr@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (Adults and Pediatrics)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Hudspeth, MD</last_name>
      <phone>843-792-0381</phone>
      <email>hudspeth@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital (Pediatrics only)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Henry-Joyce Cancer Clinic (Adults and Pediatrics)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gowri Satyanarayana, MD</last_name>
      <phone>615-322-2035</phone>
      <email>gowri.satyanarayana@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute (Adults only)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Pineiro, MD</last_name>
      <phone>214-370-1000</phone>
      <email>luis.pineiro@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Children's Medical Center (Pediatrics only)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamra Slone, MD</last_name>
      <phone>214-648-3150</phone>
      <email>tamra.slone@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center (Adults and Pediatrics)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Michael Mahadeo, MD</last_name>
      <phone>713 792-2873</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin (Adults only)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead (Pediatrics only)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Butterworth, MD</last_name>
      <phone>+61 2 9845 2185</phone>
      <email>caroline.bateman@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital (Adults only)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyam Panicker, MD, MBBS, MRCP, FRACP, FRCPA</last_name>
      <phone>+61 (2) 9845 6352</phone>
      <email>shyam.panicker@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital (Adults only)</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chambers, MBBS, MRCP, FRACP, MD</last_name>
      <phone>+61 (7) 3139 4000</phone>
      <email>daniel.chambers@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital (Adults only)</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devendra Hiwase, MD</last_name>
      <phone>+61 870740000</phone>
      <email>devendra.hiwase@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital Melbourne (Pediatrics only)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Conyers, MD, MBBS, FRACP</last_name>
      <phone>+61 (3) 9345 5658</phone>
      <email>rachel.conyers@rch.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital (Adults only)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Purtill, MD, MBBS, FRACP, FRCPA</last_name>
      <phone>+61 (8) 6152 3788</phone>
      <email>duncan.purtill@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien (Adults only)</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Worel, MD</last_name>
      <phone>+43 (1) 40400 54990</phone>
      <email>nina.worel@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège Site Sart Tilman (Adults and Pediatrics)</name>
      <address>
        <city>Liège</city>
        <state>Brussels</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willems Evelyne, MD</last_name>
      <phone>+32 4 366 72 01</phone>
      <email>e.willems@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven (Adults and Pediatrics)</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daan Dierickx, MD</last_name>
      <phone>+32 16 34 68 80</phone>
      <email>daan.dierickx@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital (Adults and Pediatrics)</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Lewis, MD</last_name>
      <phone>1 (403) 955-7203</phone>
      <email>victor.lewis@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sick Kids (Pediatrics only)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Krueger, MD</last_name>
      <phone>1 (416) 813-7654</phone>
      <phone_ext>208227</phone_ext>
      <email>joerg.krueger@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre (Adults only)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjun Law, MD</last_name>
      <phone>1 (416) 315-1147</phone>
      <email>arjun.law@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier du Haut Leveque (Adults only)</name>
      <address>
        <city>Pessac</city>
        <state>Aquitaine</state>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Forcade, MD</last_name>
      <phone>+33 557656511</phone>
      <email>edouard.forcade@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine (Adults only)</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eolia Brissot, MD</last_name>
      <phone>+33 149282621</phone>
      <email>eolia.brissot@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille (Adults and Pediatrics)</name>
      <address>
        <city>Lille cedex</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Morschhauser, MD</last_name>
      <phone>+33 320445962</phone>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades (Pediatrics only)</name>
      <address>
        <city>Paris 15</city>
        <state>Île-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicte Neven, MD</last_name>
      <phone>+33 44494822</phone>
      <email>benedicte.neven@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Pitié Salpêtrière (Adults only)</name>
      <address>
        <city>Paris Cedex 13</city>
        <state>Île-de-France</state>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Choquet, MD</last_name>
      <phone>+33 142162826</phone>
      <email>sylvain.choquet@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (Adults only)</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Cairoli, MD</last_name>
      <phone>+39 2 64441</phone>
      <email>roberto.cairoli@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo (Adults and Pediatrics)</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Comoli, MD</last_name>
      <phone>+39 0382 502716</phone>
      <email>pcomoli@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli (Adults only)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica, MD</last_name>
      <phone>+39 0630155300</phone>
      <email>simona.sica@unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu (Adults and Pediatrics)</name>
      <address>
        <city>Roma</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
      <phone>+390668592129</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla (Adults and Pediatrics)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucrecia Yanez, MD</last_name>
      <phone>+34 942202573</phone>
      <email>lucrecia.yanez@scsalud.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón - Institut de Recerca (Adults and Pediatrics)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Barba, MD</last_name>
      <phone>+34 93 274 6100</phone>
      <phone_ext>4897</phone_ext>
      <email>pbarba@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón (Adults and Pediatrics)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillen Oarbeascoa, MD</last_name>
      <phone>+34 91 586 84 43</phone>
      <email>gillen.oarbeascoa@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen del Rocio (Adults and Pediatrics)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Perez-Simon, MD</last_name>
      <phone>34-955 013260</phone>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe (Adults and Pediatrics)</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Montoro, MD</last_name>
      <phone>+34 961 245 876</phone>
      <email>juanmontorogomez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust (Adults only)</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sridhar Chaganti, MD</last_name>
      <phone>441214242000</phone>
      <email>sridhar.chaganti@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust (Adults only)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Olavarria, MD</last_name>
      <phone>+44 0208 383 2134</phone>
      <email>e.olavarria@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epstein-Barr Virus (EBV)-associated Lymphoproliferative Disease (LPD)</keyword>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>Cytotoxic T lymphocyte (CTL)</keyword>
  <keyword>Cancer After Transplant</keyword>
  <keyword>Kidney transplant</keyword>
  <keyword>Renal transplant</keyword>
  <keyword>Liver transplant</keyword>
  <keyword>Heart transplant</keyword>
  <keyword>Lung transplant</keyword>
  <keyword>Intestinal transplant</keyword>
  <keyword>Pancreas transplant</keyword>
  <keyword>Post-transplant Lymphoma</keyword>
  <keyword>Solid Organ Transplant (SOT)</keyword>
  <keyword>Bone Marrow Transplant Complications</keyword>
  <keyword>Epstein-Barr Virus-specific Cytotoxic T Lymphocytes (EBV-CTL)</keyword>
  <keyword>Hematopoietic Cell Transplant (HCT)</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation (HSCT)</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplant</keyword>
  <keyword>Allogeneic, Off-The-Shelf T-cell Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

